Haemonetics CORP 10-Q quarterly reports

Haemonetics Corporation announced its first quarter fiscal year 2027 results, showcasing a 5.6% increase in net revenues to $339.4 million and a 6.7% rise in operating income, driven by strong performance in its Apheresis and MedSurg segments.

Haemonetics Corporation reported a 19.3% increase in net income for the third quarter of fiscal 2026, reaching $44.7 million, despite a 2.7% decline in net revenues to $339.0 million, and completed the acquisition of Vivasure Medical Limited.

Haemonetics Corporation reported increased net income and diluted EPS for Q2 FY26, driven by improved gross profit and operating income despite a revenue decline from planned divestitures and customer transitions.

Haemonetics Corporation reported a 35.5% surge in operating income and a significant improvement in cash flow from operations for Q1 FY26, despite a 4.4% decline in net revenues driven by planned divestitures and customer transitions.

Haemonetics Corporation announces its Q3 2025 financial results, highlighting revenue growth driven by the Hospital segment, while Plasma and Blood Center segments face declines.

Haemonetics Corporation's second quarter of fiscal year 2025 shows revenue growth driven by the Hospital segment, but mixed results in profitability and increased operating expenses.

Haemonetics Corporation's first quarter of fiscal year 2025 saw revenue growth driven by hospital acquisitions, but operating income declined due to integration costs and increased expenses.

Haemonetics Corporation reports a 10.1% increase in net revenues for the third quarter of fiscal year 2024, driven by growth in Plasma and Hospital segments, and completes the acquisition of OpSens, Inc.